Compounds > valdecoxib

Page last updated: 2024-09-03

valdecoxib and Cardiovascular Stroke

valdecoxib has been researched along with Cardiovascular Stroke in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Birnbaum, Y; Hu, ZY; Rosanio, S; Schwarz, ER; Tavackoli, S; Uretsky, BF; Ye, Y	1
Vanchieri, C	1
Epstein, RA	1
Epstein, J; Klasser, GD	1
Aldington, S; Beasley, R; Shirtcliffe, P; Weatherall, M	1
Jugdutt, BI	1
Ashcroft, DM; Chen, LC	1
Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J	1

Reviews

3 review(s) available for valdecoxib and Cardiovascular Stroke

Article	Year
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications. Journal (Canadian Dental Association), 2005, Volume: 71, Issue:8 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Peptic Ulcer; Pyrazoles; Sulfonamides; Sulfones; Toothache	2005
Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. The New Zealand medical journal, 2005, Nov-25, Volume: 118, Issue:1226 Topics: Cardiac Surgical Procedures; Cardiovascular Diseases; Cerebrovascular Disorders; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Myocardial Infarction; Odds Ratio; Outcome and Process Assessment, Health Care; Pain, Postoperative; Risk Factors; Sulfonamides; Survival Analysis	2005
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones	2007

Other Studies

6 other study(ies) available for valdecoxib and Cardiovascular Stroke

Article	Year
Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovascular research, 2005, Feb-01, Volume: 65, Issue:2 Topics: Animals; Atorvastatin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme System; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intramolecular Oxidoreductases; Isoxazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phospholipases A; Phospholipases A2; Phosphorylation; Prostaglandin-E Synthases; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides	2005
Could Bextra increase heart risks too? Health news (Waltham, Mass.), 2004, Volume: 10, Issue:12 Topics: Coronary Artery Bypass; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Health Status; Humans; Isoxazoles; Myocardial Infarction; Stroke; Sulfonamides	2004
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. Journal of the National Cancer Institute, 2005, Apr-20, Volume: 97, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Incidence; Isoxazoles; Lactones; Membrane Proteins; Meta-Analysis as Topic; Myocardial Infarction; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. Yale journal of health policy, law, and ethics, 2005,Summer, Volume: 5, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromans; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Humans; Hypoglycemic Agents; Isoxazoles; Lactones; Myocardial Infarction; Paternalism; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; Thiazolidinediones; Troglitazone; Truth Disclosure; United States; United States Food and Drug Administration; Vasodilator Agents	2005
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation, 2007, Jan-23, Volume: 115, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Ventricular Remodeling	2007
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Follow-Up Studies; Humans; Isoxazoles; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Osteoarthritis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; United States	2008